logo-loader
viewMotif Bio PLC

Motif Bio PLC gets ball rolling for iclaprim NDA

Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB, NASDAQ:MTFB), tells Proactive's Andrew Scott they've initiated a rolling submission of a new drug application to the US Food & Drug Administration for iclaprim.

The new drug application (NDA) for their flagship next-generation antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) is expected to be completed during the second quarter of 2018.

Quick facts: Motif Bio PLC

Price: 0.61 GBX

AIM:MTFB
Market: AIM
Market Cap: £2.96 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Motif Bio announces US FDA approval deadline for its antibiotic drug

Motif Bio (LON:MTFB, NASDAQ: MTFB) CEO Graham Lumsden tells Proactive Investors the US FDA has begun the process of assessing whether the company’s next-generation antibiotic should be allowed to go on sale in the US. Motif's drug iclaprim has been granted a priority review by the...

on 08/15/2018

RNS

Holding(s) in Company

6 days, 19 hours ago

Total Voting Rights

1 week ago

Holding(s) in Company

2 weeks, 2 days ago

Directorate Changes

2 weeks, 4 days ago

Result of General Meeting

3 weeks, 1 day ago

Settlement Agreement

3 weeks, 4 days ago

2 min read